02115nam 2200505I 450 991071350870332120200611093437.0(CKB)5470000002502581(OCoLC)1156966114(EXLCZ)99547000000250258120200605d2020 ua 0engur|||||||||||txtrdacontentcrdamediacrrdacarrierDrug safety: COVID-19 complicates already challenged FDA foreign inspection program testimony before the Committee on Finance, U.S. Senate /statement of Mary Denigan-Macauley[Washington, D.C.] :United States Government Accountability Office,2020.1 online resource (26 pages) color illustrations, color mapsTestimony ;GAO-20-626-T"For release on delivery, expected at 2:30 p.m. ET, Tuesday, June 2, 2020."Includes bibliographical references.Drug safetyCOVID-19 (Disease)TreatmentUnited StatesDrugsInspectionUnited StatesDrugsUnited StatesSafety measuresEvaluationPharmaceutical industryQuality controlEvaluationDrugsSafety regulationsUnited StatesEvaluationDrug reimportationUnited StatesEvaluationImportsUnited StatesSafety measuresEvaluationCOVID-19 (Disease)TreatmentDrugsInspectionDrugsSafety measuresEvaluation.Pharmaceutical industryQuality controlEvaluation.DrugsSafety regulationsEvaluation.Drug reimportationEvaluation.ImportsSafety measuresEvaluation.Denigan-Macauley MaryUnited States.Congress.Senate.Committee on Finance,GPOGPOBOOK9910713508703321Drug safety: COVID-19 complicates already challenged FDA foreign inspection program3445754UNINA